In Ontario, Normosang is available through the Special Access Program and is funded through the Inherited Metabolic Diseases Program. It is provided as follows:
Acute intermittent porphyria
Note: Eligibility criteria for IMD program funding (all criteria must be met):
1. Diagnosis of acute intermittent porphyria should be confirmed by biochemical and molecular testing, and;
2. Hemin (Normosang) infusions should only be given under supervision and be prescribed by hematologists, gastroenterologists or metabolic specialists, and;
3. For continued funding, yearly follow up report should be submitted to the IMD program by the prescribing physician.
Source: Inherited Metabolic Diseases Program - Ontario Ministry of Health and Long-term Care
Last Updated: 10/January/2017